Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: Ian@SI who wrote (4937)	7/19/2006 5:49:34 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 12215

Ian: I forgot the major selling point.... the T2D molecules are hoped to provide the physiological benefits of GLP-1 agonists, but with small molecule, oral bioavailable drugs. ARNA, for me..... oral bioavailability JNJ two molecules approximately one fourth of potential profit phase I trial for 1st molecule launched 2/06 Message 21395498 (randomized, double-blind, placebo-controlled phase II clinical trial launched 5/06) cash, property, clinical and preclinical pipe (three projects, no partner), platform, burn